Cure My Disease

Don't miss your cure!

 Log in / Sign up

New immunotherapy cocktail takes on tough liver tumors

NCT ID NCT07175441

Disease control Sponsor: Riboscience, LLC. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This Phase 2 trial tests whether adding an experimental drug called RBS2418 to a standard immunotherapy regimen (tremelimumab plus durvalumab) can better control advanced liver cancer that cannot be removed by surgery. About 220 adults will receive either the combination or the standard therapy alone. The main goal is to see if the combination delays cancer progression and improves survival.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
RBS2418 combined with tremelimumab and durvalumab (immunotherapy drugs)
What this could lead to
If successful, this combination could offer a more effective first-line treatment for advanced liver cancer, potentially slowing tumor growth and extending survival.
What could go wrong
This is an early Phase 2 trial with only 220 participants, so results may not apply to all patients. The added drug RBS2418 may increase side effects without improving outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 220 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2026

Expected to finish

Aug 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. At least 18 years of age on the day of signing informed consent. 2. Male and female participants with advanced, unresectable HCC who are eligible to receive STRIDE regimen as first line therapy. 3. Willing to submit a pre-treatment tissue sample (archival or fresh tissue if archival is not available). Exclusion Criteria: 1. BCLC stage D disease at the time of screening or prior to first dose of RBS2418. 2. Child-Pugh class equal or higher than B8 at the time of screening or within 7 days prior to the first dose of study treatment. 3. Eligible for curative treatments (e.g., surgical resection, liver transplantation, or local ablation). 4. Evidence of rapid progression on prior therapy resulting in rapid clinical deterioration.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Advanced unresectable hepatocellular carcinoma are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Advanced unresectable hepatocellular carcinoma

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    4 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Johns Hopkins

    RECRUITING

    Baltimore, Maryland, 21218, United States

  • START Dallas Fort Worth

    RECRUITING

    Fort Worth, Texas, 76104, United States

  • University of Texas Southwestern

    RECRUITING

    Dallas, Texas, 75390, United States

  • Vanderbilt-Ingram Cancer Center

    RECRUITING

    Nashville, Tennessee, 37232, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.